Insulet Corporation

Insulet Corporation stands as a pioneering force in diabetes management technology, transforming the lives of people with diabetes through its revolutionary Omnipod insulin delivery platform. Founded in 2000 with a deeply personal mission—to free a founder's son from the burden of daily insulin injections—the company has grown from a three-person startup to a publicly traded enterprise with nearly 4,000 employees and over $2 billion in annual revenue. Headquartered in Massachusetts and listed on NASDAQ under the ticker PODD, Insulet has established itself as the leading provider of tubeless insulin pump technology, serving more than 500,000 active customers across global markets.

The company's flagship Omnipod system represents a paradigm shift in insulin delivery, eliminating the tubes, needles, and complexity associated with traditional insulin pumps. The disposable, waterproof Pod provides up to three days of continuous insulin delivery and is controlled wirelessly through a handheld device. This innovative design offers unprecedented freedom and discretion for people managing diabetes, whether they're swimming, exercising, or going about their daily activities. The Omnipod 5 Automated Insulin Delivery System, cleared by the FDA for both type 1 and type 2 diabetes, features SmartAdjust technology that automatically adjusts insulin delivery every five minutes based on continuous glucose monitor readings, predicting glucose levels up to 60 minutes ahead.

Insulet's success is built on a foundation of relentless innovation and customer-centricity. The company invested over $40 million and five years in research and development to bring its first FDA-approved product to market in 2005. Since then, it has continued to evolve its platform, launching the Omnipod DASH system in 2018 with smartphone-like controls, and the groundbreaking Omnipod 5 in 2022, which integrates advanced algorithms directly into the Pod. The company's acquisition of Automated Glucose Control in 2023 further strengthened its technology capabilities. With international operations spanning Europe, Canada, and beyond, Insulet has achieved nine consecutive years of 20% or greater revenue growth, demonstrating the global demand for its innovative approach to diabetes management.

Looking to the future, Insulet continues to push the boundaries of diabetes technology. The company is developing the Omnipod Fully Closed Loop system for type 2 diabetes—designed as the first out-of-the-box, fully automated insulin delivery system requiring no meal announcements, carb counting, or manual boluses. With robust financial performance including 69.8% gross margins and 14.9% operating margins, Insulet is well-positioned to expand its market leadership. The company's commitment to simplifying life for people with diabetes, combined with its track record of innovation and execution, ensures it will remain at the forefront of transforming diabetes care for years to come.